John R. Price - President and Chief Executive Officer

Isogenis' operations and business development efforts are lead by John R. Price, President and CEO. In addition to his efforts at Isogenis, Mr. Price is a co-founder of Greffex, Inc. and the Institute for Therapeutic Biology. He was a partner in charge of a practice segment of Deloitte & Touche and has senior management experience with American Express Tax & Business. John has obtained and created substantial financial structuring for manufacturing and financial service companies, managed and developed emerging technologies, has extensive foreign and IPO experience, and has founded and acted as chairman of a boutique investment banking firm. Mr. Price received his Master's Degree in Public Administration from Harvard University and his Undergraduate Degree from Trinity University. He is also a graduate of Culver Military Academy and a decorated Vietnam veteran. He has been a Senior Fellow at the Centre for Business and Government at the John F. Kennedy School of Government at Harvard University. He also sits on the board of directors of Brightstar Capital, LLC and is an advisor to the State Securities Commission of the Republic of Vietnam.

Uwe Staerz, M.D., Ph.D. - Chairman of the Board and Chief Scientific Officer

Dr. Staerz received an M.D. degree from the Eberhard-Karls-University in Tuebingen, Germany, and a Ph.D. in Biology/Immunology from the University of California, San Diego, CA. Dr. Staerz provides some of the necessary funding as the company's founding member. In conjunction with Dr. Konigsberg (see below), he established Isogenis' research facility and initiated its in-house research program under the name Biohybrid, Inc. He is the inventor or co-inventor of three issued patents dealing with activating and suppressing hybrid antibodies (US Patent 5,078,998 - Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigens; US Patent 6,060,054 - Product for T lymphocyte immunosuppression; US Patent 6,264,950 - Product and process for T lymphocyte immunosuppression.) He is a recognized scientific leader in the fields of T-lymphocyte suppression and development and has published numerous manuscripts in prestigious scientific journals. As Isogenis' Chief Scientific Officer, Dr. Staerz provides his scientific expertise and creates the Company's product and patent strategies.

Paula J. Konigsberg, Ph.D., MA - Senior Vice President of Research and Development

Paula comes to Isogenis from California where she had been a Senior Research Scientist at Vestar, Inc., successfully developing liposome-based drug delivery systems for immune disorders as well as bringing in extra-mural funding for the company. She and Uwe decided to start a biotech company in Denver, and Isogenis is the result of their efforts. She holds a Bachelor of Arts degree in Biochemistry from the University of California, Berkeley, a Ph.D. in Biochemistry/ Molecular Biology from the State University of New York, Stony Brook, and a Masters in Technology Management from The University of Denver.

Yan Qi, M.D., MSM - Chief Scientist and Vice President

In his 16+ years of experience, Dr. Qi has been active in clinical and basic biomedical research in both the biotech industry and academia in the United States and China. He has held positions as a surgeon at the China-Japan Friendship hospital and as a postdoctoral research fellow and a scientist through both the Colorado Health Science Medical Center and National Jewish Center, and is currently the chief Scientist at Isogenis. He and Dr. Staerz developed a novel biological mechanism exploiting a phenomenon called "engineered veto effect" for immune therapy. This technology has applications in transplantation, auto-immune disease, and gene therapy. Dr. Qi holds an M.D. degree from Shandong Medical University, an MSM (Master of Science Management) degree from Colorado Technical University, and a MS degree from China-Japan Clinical Medical Research Institute.

Xianghua Zhang, M.D. - Senior Scientist

Dr. Zhang received his M.D. from Shanghai Medical University, the second highest ranked university in China. From there, Xianghua went on to earn his Masters Degree in microbiology at the University of Louisville. After ten years of research experience in the Department of Immunology at National Jewish Medical and Research Center, Dr. Zhang is now the Senior Scientest at Isogenis. Xianghua remarks: "I am truly excited about our research project because I know it could positively affect the lives of millions of people."

Erin K. Spiegel, Ph.D. - Scientist

Erin is originally from Lincoln, Nebraska, where she obtained her Bachelor of Science degree in animal science from the University of Nebraska. Erin studied the genetics of reproduction in pigs as an undergraduate, and moved to Denver to work on her Ph.D. in human medical genetics at the University of Colorado Health Sciences Center, which involved the creation of a mouse model for autism and psychomotor delay. After graduating, Erin joined Isogenis and is involved in projects developing adenovirus vectors and viral packaging systems.

Janae Wheeler - Research Associate

A native of Colorado, Janae Wheeler graduated from Colorado State University's School of Veterinary Medicine and Biomedical Sciences with a Bachelor's degree in Microbiology in 2000. She has been with Isogenis for over 5 years. Ms. Wheeler is working closely on the Islet Transplantation project, as well as our various recombinant adenovirus productions. She is studying Diabetes Type I, and is also involved heavily in molecular biology for gene design and expression. In addition to her research, Ms. Wheeler is also responsible for the day to day operations of the company.

Coral Cruz - Research Associate

Coral graduated in 1998 from Mayaguez Campus of the University of Puerto Rico with a degree in biology. She moved to Denver in 1999 to work in a molecular biology lab at the Webb Waring Institute at the University of Colorado Health Sciences Center. Since the beginning of 2002, she has been working on our adenovirus project at Isogenis.